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inﬂammation markers on overall survival (OS) and cancer-speciﬁc survival
(CSS). In turn, another independent set of 225 patients were used for
validation. Finally, we performed survival analysis in the combined cohort
consisting of 420 UTUC patients.
Results: The predictive value of RDW and WBC count on outcome was
replicable in different cohorts. Multivariate analysis showed high RDWwas
independently associated with poor OS (P< 0.001), and WBC count was a
signiﬁcant prognosticator for both OS and CSS (both P< 0.001). In subgroup
analysis, we found the prognostic signiﬁcance of RDW for OS was limited in
organ-conﬁned disease (pT2 without pN+). More importantly, a clear
survival difference can be demonstrated by combining RDWandWBC count
with other known prognostic factors in the risk stratiﬁcation model.
Conclusion: RDW and WBC count have the advantage of their common
accessibility and are useful markers to predict outcome of UTUC in the
preoperative setting. RDW and WBC count could provide additional
prognostic value and help physicians identify patients at high risk for
mortality and formulate individualized treatment strategy.
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Background: Human bladder cancer (BC) cells exhibited a high basal level
of autophagic activity demonstrated by accumulating of acridine orange
(AO)-stained acidic vesicular organelles (AVOs) in BC cells. In this study, we
aim to investigate the cytotoxicity effects of AO on the human BC cell lines
under blue-light exposure.
Materials and Methods: To evaluate phtotoxicities of AO toward human
bladder cancer cells, we designed and developed a blue-light source
equipped with 6 blue-light LED (peak wavelength: 443.7 nm). The AO
relocalization in treated-BC cells was recorded using a ﬂuorescence mi-
croscopy equipped with a color CCD camerain a real-time fashion. The cell
viability was determined using (a) WST-1 reagents (immediately after
treatment for 1 hour), (b) continuous quantiﬁcation with Cytation 5 Cell
ImagingMulti-mode reader (Biotek Instruments, Inc., for 24 hours), and (c)
time-lapse imaging with a cell imaging recorder (Cytosmart System,
Lonza; for 36 hours) in human immortalized uroepithelial (SV-Huc1) and
BC cell lines (5637 and T24) treated with indicated concentration of AO
with or without blue light exposure.
Results: The AO relocationwas clearlymonitored by ﬂuorescentmicroscopy
with decreased red ﬂuorescent intensity over exposure duration within 5-
15 secounds in BC cells. Treatment ofAO or blue-light exposure alone did not
cause a signiﬁcant decrease of cell viability in BC cells. However, we found
that AO exhibited a dose-dependent increment of cytotoxicity toward BC
cells with blue-light exposure (AO-PDT). In addition, this phenomenon was
more prominent in human BC cell lines compared to SV-Huc1 cells. These
results suggested that AO, as a photosensitizer, disrupts acidic organelles in
BC cells under blue light irradiation in BC cells.
Conclusion: Blue light irradiation in BC cell treated with AO causes severe
cell death. The photodynamic effect can be applied clinically to an existing
instrument, namely narrow band image endoscopic system, to deliver blue
light. The AO-PDT may serve as a novel therapeutic strategy to reduce
recurrence or against human bladder cancer in the future.
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University, Taoyuan, TaiwanPurpose: In contrast to PSA for prostate cancer, no reliable bladder cancer
biomarker is currently widely applicable for the detection and follow-up of
bladder cancer. We employed a strategy combining isotopic dimethylation
labeling coupled with liquid chromatography-tandem mass spectrometry
(LCMS/MS) to discover bladder cancer biomarkers in urinary micropar-
ticles isolated from hernia (control) and bladder cancer patients.
Materials and Methods: The urine specimens of bladder cancer patients
and age-matched hernia patients (n¼ 81) were collected in the morning of
surgery. The surgically resected bladder tumors were all pathologically
identiﬁed and determined into 3 groups for comparison; namely, Low-
grade/Early stage (LgEs, n¼ 40), High-grade/Early stage (HgEs, n¼ 63), and
High-grade/ Advanced-stage (HgAs, n¼ 37).
Results: A total of 107 proteins out of 2964 proteins were identiﬁed in this
approach as candidate biomarkers. Differences in the concentrations of 29
proteins were precisely quantiﬁed by LCMRM/MS. There were 24 pro-
teins changed signiﬁcantly (p< 0.05) between bladder cancer and hernia.
TACSTD2 concentrations measured by LC-MRM/MSwere 6.5-fold higher in
bladder cancer urinary microparticles than in hernia urinary microparti-
cles. In raw urine specimens (n¼ 221) using ELISA, the area-under-the-
curve values of TACSTD2 was 0.80.
Conclusion: Our study revealed that TACSTD2 showed strong association
with bladder canLcer in urine specimens, and thus represents a potential
biomarker for noninvasive screening for bladder cancer.
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Purpose: Cancer stem cells were considered to be the genesis of cancer
and account for cancer initiation, progression, and recurrence. Studies
have highlighted a role for Hexokinase 2 (HK2) in facilitating tumor growth
and lactate production, which is downstream product of HK2 reaction in
cancer cells. Tumor cells can extrude and shuttle lactate to neighboring
cancer cells, adjacent stromal cells, and vascular endothelial cells to induce
signaling molecular change. However, in tumor microenvironment, the
molecular mechanisms underlying this association of tumor lactate shut-
tle, HK2 activity and cancer metastases were not well established. In this
study, we explored the role of lactate shuttle induced by HK2 in cancer
stem cell formation and epithelial-mesenchymal transition (EMT) be-
tween bladder cancer cells in vitro and in vivo.
Materials and Methods: The endogenous HK2 in human bladder cancer
(TCCSUP, J82 and TSGH8301) and normal (SVHUC) cells was examined by
immunoblot and immunoﬂuoscence. Effects of lactate exposure on cell
proliferation, morphologic change and cancer stem cell phenotype were
analyzed in human bladder cancer cells. Stable HK2-overexpression and
eknockdown clones were also examined for their effects on EMT, lactate
secretion, NF-kB phosphorylation and CD133 activity in vitro and mouse
models. The animal survival and lung metastasis were assessed in a mouse
subcutaneous model using TSGH8301 cells with HK2-overexpression
clones. All statistical tests were two-sided.
Results: The HK2 expression was signiﬁcantly higher in bladder cancers
compared with normal cells. The urine lactate detection was higher in
human bladder cancers than in non-cancer subjects (204.9 vs 54.79 mM;
P< 0.001). Stable HK2 overexpression induced cell proliferation, and
showed morphologic changes with gain of cancer stem cell markers. HK2
knockdown also reduced lactate extrusion in vitro. In response to lactate
exposure, nuclear translocation of NF-kB phosphorylation and Twist1 as
well as mesenchymal markers was promoted in human bladder cancer
cells. In addition, lactate exposure enhanced CD133 activity in vitro. Inmice
bearing subcutaneous tumors, increased tumor growth and lung metas-
tasis were observed in stable HK2-overexpression cancers compared with
mock counterparts (survival, P¼ 0.034). In animal models, HK2-over-
expression cancers also induced morphologic change and CD133 activity.
# These authors contributed equally to this work.
Abstracts / Urological Science 27 (2016) S1eS23 S3Conclusion: High HK2 expression in bladder cancers induced over-
secretion of lactate, which was associated with metastatic behaviors
through the cancer stem cell formation, EMT promotion and nuclear
translocation of phosphorylated NF-kB and Twist1. HK2 may be a novel
oncoprotein and play as target for bladder cancer therapy.
Podium-2
Oncology
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Purpose: According to our previous results in methylated-CpG island re-
covery assay (MIRA) and RNA expression array, methylated status of
Interferon regulatory factor 6 (IRF6) could be observed in most of renal cell
carcinoma (RCC) cases, and presented a negative correlation with gene
expression, especially in clear cell type of RCCs. The aim of this study is to
clarify the clinical signiﬁcance and role of IRF6 in RCC.
Materials and Methods: 105 pairs of clinical RCC patients and RCC cell
lines have involved in the current study. Real-time PCR assay was used to
detect the expression of IRF6 on all cases. Western blot assay was per-
formed to detect whether the expression of IRF6 in the 5-aza-2'deoxy-
cytidine treated RCC cells could be restored. The IRF6 gene expression level
in normal and RCC tissues were shown byeDCT and applied by the paired-
T test.
Results: The variant and lower level gene expression of the IRF6 could be
observed in most of RCC cell lines. After cells treated with 5-aza-2'deox-
ycytidine, the expression of IRF6 was restored. In the real-time PCR of IRF6
in RCC tissues, the mean eDCT was 8.0 in normal tissue and 11.5 in RCC
tissue with signiﬁcantly different (P¼ 0.013).
Conclusion: Our ﬁndings demonstrated that the aberrant expression of
IRF6 in RCCs was due to methylation. Also, the expression level of IRF6 was
higher in normal tissues as compared with tumor tissues. Besides, it has
been described that IRF6 could function as a tumor suppressor since it
could inhibit tumor invasion and migration in squamous cell carcinoma.
Based on these results, we suggest that IRF6 may play an important role in
the pathophysiology of RCC. However, further cell viability and correlation
with the clinical information should be further analyzed in the future.
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Purpose: Cisplatin has been used to treat bladder cancer (BC), however,
cisplatin alone is not very effective, and the combinations of gemcitabine/
cisplatin is now the ﬁrst-line chemotherapy. Moreover, bladder tumor
exhibits high basal level of autophagy. In this study, we investigated if
cisplatin induces more autophagy in human BC cells, and whether inhi-
bition of cisplatin-induced autophagy enhances apoptosis that leads to
cancer cell death.
Materials and Methods: The autophagy status in cisplatin-treated RT4
(grade I), 5637 (grade II), and T24 (grade III) human bladder cancer cells
was performed by the detection of microtubule-associated light chain 3
form II (LC3-II) and aggregation of LC3 puncta using Western blots and
immunoﬂuorescent staining, respectively. Moreover, the formation ofautophagolysosome was detected using transmission electron microscopy
to conﬁrm the increased number of autophagosomes in cisplatin-treated
T24 cells. The cell viability in cells treated with cisplatin with or without
the autophagy inhibitor, baﬁlomycin A1 (BafA1), was accessed by WST-1
cell viability kit. To investigate the signaling pathway involved in cisplatin-
induced autophagy, the activation of AKT, ERK, AMPK and MAPK and the
inhibition of mTOR in cisplatin-treated cells were detected by Western
blot. Induced apoptosis was determined by the detection of cleaved cas-
pase 3, cleaved PARP, the caspase 3/7 activity and the level DNA frag-
mentation in treated-cells.
Results: The processing of LC3-II was elevated in cells treated with
increased concentration of cisplatin, suggesting cisplatin induces auto-
phagy. Detection of autophagy ﬂux (by blocking autophgosome to lyso-
somes fusion using Baf A1) in 5637 and T24 cells, and the direct
observation of autophagolysosome formation in cisplatin-treated T24 cells
using TEM further conﬁrmed that cisplatin indeed triggers autophagy.
Advanced bladder cancer cells (5637 and T24) were more resistant to
cisplatin than RT4, suggesting autophagy acts as a survival mechanism in
high grade BC cells. While no response was found in AMPK, the activation
of AKT, ERK and MAPK signaling and inhibition of mTOR was detected in
cisplatin treated cells. However, pretreatment of speciﬁc inhibitors of ERK,
MAPK did not attenuated cisplatin-induced autophagy suggests these
pathways are not involved in the induction of autophagy. Finally, reduced
cell viability and induced apoptosis were detected in cisplatin-treated cells
pretreated with autophagy inhibitor suggesting that inhibition of auto-
phagy enhances cancer killing effect of cisplatin in human BC cells.
Conclusion: Cisplatin induces autophagy in human BC cells, and auto-
phagy inhibition enhances apoptosis in cisplatin-treated cells. This study
suggests a new therapeutic paradigm for the treatment of bladder cancer.
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Purpose: Autophagy is activated and may contributed to cisplatin-resis-
tance in cisplatin-treated bladder cancer (BC) cells. It is reasonable to
speculate that Inhibition of autophagy enhances the anti-cancer effects of
cisplatin in BC cells. In this study, we characterized the role of miR-30a-5p,
which is down-regulated in BC cells, in the coordination of apoptosis and
autophagy by accessing its potential targeting protein, ATG5 and beclin-1
(BECN1).
Materials and Methods: The BC cell lines, 5637 (grade II) and T24 (grade
III) and immortalized human uroepithelium cells (SV-HUC-1) were used in
this study. To elevate the expression level of miR-30a-5p, a small RNA
expression vector bearing matured sequence of miR-30a-5p (pSM-30a)
was constructed and transfected into human BC cells. The expression level
of miR-30a-5p was detected by stem-loop miRNA qPCR. Protein level of
ATG5 and BECN1, both are predicted targets of miR-30a-5p, was accessed
by Western blot. Autophagy detection in cisplatin-treated cells was per-
formed by monitoring LC3-II processing by Western blot. Induction of
apoptosis in cisplatin-treated cells with or without the over-expressed
miR-30a-5p was detected by the detection of cleaved caspase-3 and PARP.
Results: The expression level of miR-30a-5p was elevated up to 8 fold in
pSM-30a transfected BC cells according to miRNA qPCR. The autophagy
activity in BC cells increased after cisplatin treatment as indicated by the
enhanced processing of LC3-II. As ATG5 and BECN1 were predicted targets
for miR-30a-5p by TargetScan, forced expression of miR-30a-5p signiﬁ-
cantly reduced the expression level of ATG5, BECN1 and LC3-II induced by
cisplatin. The blockage of autophagy by miR-30a-5p expression or baﬁlo-
mycin A1 (Baf A1) signiﬁcantly decreased cell viability and increased
apoptosis in cisplatin-treated BC cells.
